All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld Perspectives » Lessons learned from You-Know-Who

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

Lessons learned from You-Know-Who

Sep. 2, 2015
By Mari Serebrov
No Comments

Puma April 9, 2014Duchesnay Inc.’s 15-minutes of fame for its morning sickness drug arguably turned into a few hours’ worth by time the drugmaker complied with an FDA warning letter demanding a corrective ad to offset the omission of risk information in paid social media endorsements by She-Who-Must-Not-Be-Named in the serious biopharma world.

The first 15 minutes for Diclegis (doxylamine succinate and pyridoxine hydrochloride)came with You-Know-Who’s tweets and posts to her millions of followers on Facebook and Instagram. That fame increased exponentially when the FDA handed down the warning letter last month, daring to name the infamous reality TV maven and setting mainstream media, talk shows AND trade publications atwitter with the news.

Yes, the “Dark Goddess” even got her name in BioWorld, which routinely covers FDA warning and untitled letters as they often offer guidance to drug- and device-makers. But the lessons learned from this letter are probably not what the FDA thought it was teaching.

To comply with the warning letter, Duchesnay had to get a “corrective” ad out to much-the-same audience that received the first one. So once again, it enlisted the power of She-Who-Must-Not-Be-Named, sending its message via the magic of social media to millions of You-Know-Who’s followers. This time Duchesnay waved its own social media wand, tweeting more attention to the maven’s posts. And the media storm ensued.

What the FDA intended as a slap on the hand turned into a publicity blitz for Diclegis. Thus, the moral of the story is: You can’t buy this kind of promotion. But you can conjure it – if you think the fame is worth more than a mere mortal warning letter.

The question now is whether more drug and device companies follow Duchesnay’s lead in aligning themselves ever more closely with the likes of You-Know-Who in the quest of establishing their products as household names.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing